Status Epilepticus Evidence-Based Management and Escalation Algorithms for the Hospitalist скачать в хорошем качестве

Status Epilepticus Evidence-Based Management and Escalation Algorithms for the Hospitalist

In this episode of Hospital Medicine Unplugged, we sprint through status epilepticus—stop the seizure fast, escalate therapy on time, protect the brain, and treat the cause before refractory disease sets in. We begin with the modern definition that changed emergency care. Status epilepticus is now defined as ≥5 minutes of continuous seizure activity or ≥2 seizures without return to baseline. The old 30-minute threshold is obsolete because neuronal injury and benzodiazepine resistance begin early, driven by GABA receptor internalization within minutes of sustained seizure activity. That’s why treatment must begin within the first 5–10 minutes. The stakes are high: incidence is 10–40 per 100,000 annually, with 10–20% adult mortality, rising sharply in refractory cases, elderly patients, and acute symptomatic etiologies such as stroke or hypoxic injury. Next comes the first-line intervention—benzodiazepines within 5–10 minutes. These remain Level A evidence therapy and terminate seizures in roughly 65–70% of cases when given promptly and at adequate doses. Three effective options: • IV lorazepam 0.1 mg/kg (max 4 mg), may repeat once • IM midazolam 10 mg (0.3 mg/kg in children) — preferred if IV access unavailable • IV diazepam 0.15 mg/kg, may repeat once The biggest real-world mistake isn’t drug choice—it’s delay and underdosing. If seizures persist, move quickly to second-line “urgent control” therapy (10–20 minutes). The landmark ESETT trial compared levetiracetam, fosphenytoin, and valproate in benzodiazepine-refractory status epilepticus and fundamentally changed practice. The key finding: all three drugs work equally well, stopping seizures in about 47–52% of patients. Recommended doses: • Levetiracetam 60 mg/kg (max 4500 mg) • Fosphenytoin 20 mg PE/kg • Valproate 40 mg/kg Because efficacy is equivalent, patient factors guide the choice: • Cardiac disease → avoid fosphenytoin (hypotension/arrhythmia risk) • Pregnancy or liver disease → avoid valproate • Simplest safety profile → levetiracetam Other alternatives include lacosamide or phenobarbital, though ESETT drugs remain the most widely used. When seizures continue despite these steps, the patient has entered refractory status epilepticus, which occurs in 23–43% of cases. At this stage, escalation means ICU care, intubation, and continuous EEG monitoring. Third-line therapy involves continuous anesthetic infusions designed to suppress cortical activity: • Propofol (20–200 mcg/kg/min) — rapid onset but risk of propofol infusion syndrome with prolonged use • Midazolam infusion — commonly used but tachyphylaxis develops • Pentobarbital coma — powerful seizure suppression but high rates of hypotension and prolonged sedation Most modern practice favors propofol or midazolam over barbiturate coma. A newer strategy gaining traction is ketamine, an NMDA receptor antagonist with a completely different mechanism from GABAergic drugs. Unlike other anesthetics, ketamine preserves blood pressure and respiratory drive, making it a useful adjunct in refractory disease. If seizures continue ≥24 hours despite anesthetic therapy, the condition becomes super-refractory status epilepticus, a devastating scenario with mortality approaching 40–50%. Management expands to include: • Ketamine infusions • Immunotherapy (steroids, IVIG, plasmapheresis) when autoimmune etiologies are suspected • Ketogenic diet • Neuromodulation or epilepsy surgery in select cases Two particularly challenging syndromes fall into this category: NORSE (New Onset Refractory Status Epilepticus) and FIRES (Febrile Infection-Related Epilepsy Syndrome), often requiring aggressive immunologic treatment. Throughout all stages, clinicians must identify and treat the underlying cause—the strongest determinant of outcome. Prognosis varies dramatically depending on response to therapy: • Benzodiazepine-responsive SE: ＜5% mortality • Second-line responsive SE: ~10–15% mortality • Refractory SE: 20–40% mortality • Super-refractory SE: up to 50% mortality Poor outcomes are associated with older age, acute symptomatic etiologies (stroke, infection, hypoxic injury), prolonged seizures, and nonconvulsive status epilepticus with coma, which is one of the strongest predictors of mortality. Finally, systems matter. Hospitals that implement structured status epilepticus protocols dramatically improve outcomes. Protocol adherence reduces time to second-line therapy from nearly an hour to about 20 minutes and lowers ICU transfer rates. We close with the practical escalation algorithm every inpatient team should know: • 0–5 minutes: ABCs, glucose check, IV access, prepare meds • 5–10 minutes: benzodiazepine (lorazepam, midazolam, or diazepam) • 10–20 minutes: second-line AED (levetiracetam, fosphenytoin, or valproate) • 20–40 minutes: prepare for intubation, initiate EEG monitoring • Refractory SE: continuous anesthetic infusi...